Atossa Genetics (NASDAQ:ATOS) Announces Earnings Results

Atossa Genetics (NASDAQ:ATOS) announced its quarterly earnings data on Friday. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12), FiscalAI reports.

Atossa Genetics Trading Down 1.2%

Shares of NASDAQ ATOS traded down $0.07 during midday trading on Friday, reaching $5.60. 31,395 shares of the stock were exchanged, compared to its average volume of 61,457. The business has a 50-day simple moving average of $5.18 and a two-hundred day simple moving average of $8.28. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research note on Monday, April 20th. HC Wainwright raised their price objective on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Finally, Ascendiant Capital Markets reduced their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $36.33.

Hedge Funds Weigh In On Atossa Genetics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Hudson Bay Capital Management LP bought a new position in shares of Atossa Genetics during the second quarter worth $26,000. JPMorgan Chase & Co. lifted its position in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after acquiring an additional 35,474 shares in the last quarter. &PARTNERS bought a new stake in Atossa Genetics in the 4th quarter valued at $25,000. Bank of America Corp DE lifted its position in Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares in the last quarter. Finally, XTX Topco Ltd lifted its position in Atossa Genetics by 581.2% in the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after acquiring an additional 144,412 shares in the last quarter. 12.74% of the stock is owned by institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.